Proprietary Transdermal PlatformA focused, proprietary transdermal technology creates a durable competitive moat in patch-based drug delivery. Owning formulation and manufacturing know-how supports licensing, supply contracts and long-term R&D partnerships, enabling recurring revenues beyond single-product cycles.

Very High Product Gross MarginsExceptionally high gross margins indicate strong product-level economics for transdermal offerings. If SG&A and R&D are controlled or commercialized via partners, these margins can underpin durable profitability and attractive returns on incremental revenue over the medium term.

Conservative Leverage / Minimal DebtEffectively zero debt reduces financial risk and gives strategic flexibility to fund development, strike licensing deals, or weather commercialization delays. A strong equity cushion versus assets also provides runway for financing activities without immediate solvency pressure.

Bears Say

Persistent Operating And Net LossesSustained large operating and net losses undermine long-term shareholder value and signal that core operations are not yet profitable. Continued losses increase likelihood of dilution or external financing and constrain the firm's ability to reinvest internally for growth.

Consistent Negative Operating/free Cash FlowRepeated negative operating and free cash flow demonstrates structural cash burn and reliance on financing to sustain R&D and operations. This limits the company's ability to self-fund launches or scale manufacturing and raises execution risk over the next several quarters.

Revenue Volatility And Extreme Negative MarginsWide top-line swings coupled with extreme negative margins indicate a mismatch between revenue and fixed costs/R&D. Even strong revenue spikes have not translated to operating leverage, suggesting structural issues in cost base or commercialization scale that threaten long-term margin sustainability.

4586 FAQ

What was Medrx Co., Ltd.’s price range in the past 12 months?

Medrx Co., Ltd. lowest stock price was ¥55.00 and its highest was ¥225.00 in the past 12 months.

What is Medrx Co., Ltd.’s market cap?

Medrx Co., Ltd.’s market cap is ¥6.65B.

When is Medrx Co., Ltd.’s upcoming earnings report date?

Medrx Co., Ltd.’s upcoming earnings report date is May 08, 2026 which is in 80 days.

How were Medrx Co., Ltd.’s earnings last quarter?

Medrx Co., Ltd. released its earnings results on Feb 13, 2026. The company reported -¥2.6 earnings per share for the quarter, missing the consensus estimate of N/A by -¥2.6.

Is Medrx Co., Ltd. overvalued?

According to Wall Street analysts Medrx Co., Ltd.’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Medrx Co., Ltd. pay dividends?

Medrx Co., Ltd. does not currently pay dividends.

What is Medrx Co., Ltd.’s EPS estimate?

Medrx Co., Ltd.’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Medrx Co., Ltd. have?

Medrx Co., Ltd. has 59,365,100 shares outstanding.

What happened to Medrx Co., Ltd.’s price movement after its last earnings report?

Medrx Co., Ltd. reported an EPS of -¥2.6 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -0.885%.

Which hedge fund is a major shareholder of Medrx Co., Ltd.?

Currently, no hedge funds are holding shares in JP:4586

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Medrx Co., Ltd.

MedRx Co., Ltd, a pharmaceutical formulation development company, provides pharmaceutical drugs based on the transdermal absorption system in Japan. The company develops medicines based on Ionic liquid transdermal system (ILTS) and Nano-sized Colloid Transdermal System (NCTS); and researches and develops painless transdermal administration system for vaccines, nucleic acid medicines, protein medicines, etc. Its products pipeline includes MRX-4TZT, which is in phase I clinical trials for the treatment of spastic paralysis; MRX-9FLT that is in phase I clinical trials to treat chronic, cancer, and severe pain; and MRX-7MLL and MRX-6LDT that is in pre-clinical trials to treat Alzheimer's disease and chronic pain, as well as MRX-5LBT that has completed the clinical trials for the treatment of postherpetic nerve pain. MedRx Co., Ltd was incorporated in 2002 and is headquartered in Higashikagawa, Japan.